Analysts Set Beam Therapeutics Inc. (NASDAQ:BEAM) Price Target at $46.08

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has received an average rating of “Hold” from the twelve brokerages that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target […]

Leave a Reply

Your email address will not be published.

Previous post China seeks exemption from US sanctions for Russian LNG – Reuters
Next post Domino’s Pizza, Inc. (NYSE:DPZ) Given Average Rating of “Moderate Buy” by Analysts